Advaxis Reports Second Quarter Ended April 30, 2021 Financial Results and Provides a Business Update

NEXT STORY
Cellectis’ Innovation Days event highlighted New Product Development, New Genome Surgery Platform .HEAL, and Manufacturing Capabilities
PREV STORY
PDS Biotech Announces Proposed Offering of Common Stock
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Conference call regarding Elekta’s Interim Report for May-January 2015/16

STOCKHOLM, February 17 – Elekta (EKTA-B.ST) will publish its interim report for May-January 2015/16 ...

author_avatar
NASDAQ Market News

Chiesi and Holostem Announce FDA Orphan Drug Designation for GPLSCD01 for treatment of Limbal Stem Cell Deficiency (LSCD)

Investigational therapy uses individual patient’s own stem cells to potentially regenerate and repair damaged ...

author_avatar
NASDAQ Market News

AnaptysBio To Present Data from ANB020 Phase 2a Atopic Dermatitis Trial at AAD Annual Meeting

SAN DIEGO, Feb. 07, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology ...

author_avatar
NASDAQ Market News